ReNeuron’s full year results highlighted the progress of its stem cell therapy candidates with data for its CTX stem cell therapy candidate for stroke (Phase II) and critical limb ischaemia (Phase I) due in 2016 and hRPC stem cell therapy candidate for retinitis pigmentosa due to commence a Phase I/II trial in 2015. The £68.4m placing also announced this morning strengthens the group’s balance sheet and enables it to progress its pipeline through to H1 2019 when two of its programmes should have ....
10 Jul 2015
Full year results and £68.4m placing
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Full year results and £68.4m placing
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
10 Jul 2015 -
Author:
Sheena Berry -
Pages:
3
ReNeuron’s full year results highlighted the progress of its stem cell therapy candidates with data for its CTX stem cell therapy candidate for stroke (Phase II) and critical limb ischaemia (Phase I) due in 2016 and hRPC stem cell therapy candidate for retinitis pigmentosa due to commence a Phase I/II trial in 2015. The £68.4m placing also announced this morning strengthens the group’s balance sheet and enables it to progress its pipeline through to H1 2019 when two of its programmes should have ....